Business Wire

NETSCOUT Combines Leading Global Threat Intelligence With Machine Learning to Protect Enterprises From Rapidly Spreading Dynamic DDoS Attacks

11.7.2023 13:05:00 EEST | Business Wire | Press release

Share

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT), a leading provider of performance management, cybersecurity, and DDoS attack protection solutions, today released its latest version of Arbor Edge Defense (AED) which includes new ML-based Adaptive DDoS Protection.

According to NETSCOUT's latest DDoS Threat Intelligence Report, there has been a significant increase in a new breed of dynamic DDoS attacks that use multiple vectors and techniques to launch botnet-based, direct-path, state exhaustion, and application-layer attacks designed to evade conventional static network and cloud-only-based DDoS defense.

Every enterprise is at grave risk today if they don’t deploy an effective DDoS solution on-premises to protect their network edge, internet-facing services, and critical stateful infrastructure such as firewalls and load balancers from these constantly evolving attacks. Attackers can send dynamic direct-path DDoS traffic at any time, and they can quickly change attack vectors during the attack making them nearly impossible to defend without the right technology. With AED’s Adaptive DDoS Protection, IT teams now have a scalable, always-on stateless packet processing solution that uses unmatched visibility into more than 50% of all internet traffic, global, real-time DDoS attack threat intelligence, decades of DDoS mitigation experience, and machine learning (ML) software intelligence to automatically detect, adapt to, and mitigate dynamic DDoS attacks.

“As cyber threats become more sophisticated and dynamic, IT teams need to out-smart bad actors with the ability to adapt and surgically block unwanted traffic at the network edge,” said Scott Iekel-Johnson, AVP, DDoS and Threat Intelligence at NETSCOUT. “With unmatched real-time visibility into global DDoS attack activity and decades of mitigation experience, no one knows more about DDoS attacks than NETSCOUT. With AED’s Adaptive DDoS Protection, enterprises can take advantage of our DDoS attack expertise and minimize unnecessary workloads that force expensive upgrades with an always-on product that can scale to protect every edge from a single pane of glass.”

Automated AED Protects Enterprises from Threats

Deployed at the Internet edge in front of any firewall, AED screens incoming and outgoing traffic using stateless packet processing, global DDoS threat intelligence, and ML to block inbound cyber threats, including DDoS attacks and other bulk malicious traffic. It protects and reduces the load on firewalls, load balancers, or VPN concentrators and stops the proliferation of malware within an organization. AED can also block outbound communications sent from compromised internal devices to sites run by bad actors to prevent data breaches and other malware activity. It contains the threat while giving the IT team time to investigate and remove it before it can cause further damage. In the event of a large volumetric DDoS attack, AED’s cloud signaling feature integrates with cloud DDoS protection providers, including NETSCOUT’s Arbor Cloud, to intelligently and automatically coordinate attack response between cloud-based volumetric protection and on-premise adaptive DDoS attack protection.

Visibility into 50% of All Internet Traffic

NETSCOUT ASERT, the company’s expert security research and DDoS attack mitigation team, works with over 500 Internet Service Providers (ISPs) to maintain a unique sensor network called ATLAS. With over 400 Tbps of international transit traffic received every second of every day from 93 countries, 600 industry verticals, and more than 31,000 autonomous systems, ATLAS provides ASERT with unmatched visibility into more than 50% of all internet traffic and real-time DDoS attack activity. ASERT analyzes the ATLAS data and distributes its findings to the Arbor Edge Defense (AED) solution via the ATLAS Intelligence Feed (AIF). AIF continually arms AED with highly curated intelligence that constantly updates the IP addresses of bots and reflectors/amplifiers actively participating in DDoS attacks around the globe. Created from real-world ASERT mitigation experience, AED’s Adaptive DDoS defense capabilities use ML-based algorithms to automatically recommend changes to attack countermeasures designed to stop dynamic DDoS attacks.

To learn more about how Adaptive DDoS Protection for AED automatically protects networks from dynamic DDoS attacks, visit our website.

About NETSCOUT

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance and availability disruptions through the company’s unique visibility platform and solutions powered by its pioneering deep packet inspection at scale technology. NETSCOUT serves the world’s largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com or follow @NETSCOUT on LinkedIn, Twitter, or Facebook.

©2023 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Visibility Without Borders, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Maribel Lopez
Manager, Marketing & Corporate Communications
+1 781 362 4330
maribel.lopez@netscout.com

Chris Shattuck
Finn Partners for NETSCOUT
+1 404 502 6755
NETSCOUT-US@FinnPartners.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye